Halka K G, Caro J, Erslev A J
J Lab Clin Med. 1987 Jun;109(6):698-705.
Mice treated with busulfan develop chronic latent marrow aplasia characterized by near-normal peripheral leukocyte counts, hematocrits, and marrow cellularity but very reduced stem cell (CFU-S) and progenitor cell (CFU-GM) populations. To determine whether the lesion is primarily in the stem cells or whether there is also a microenvironmental component we have used the Dexter-type long-term marrow cultures. Normal marrow maintains hemopoiesis for several weeks to months in such cultures, whereas "busulfan-marrow" will not support long-term growth. When normal marrow cells were transplanted onto an established adherent layer, whether derived from normal or busulfan marrow, normal hemopoiesis was established. However, busulfan-treated marrow cells would not establish hemopoiesis even when transplanted onto a normal stem cell-depleted adherent layer. It appears, therefore, that the primary lesion induced by busulfan is in the stem cells rather than in the microenvironment.
用白消安处理的小鼠会发展出慢性潜伏性骨髓再生障碍,其特征为外周白细胞计数、血细胞比容和骨髓细胞密度接近正常,但干细胞(CFU-S)和祖细胞(CFU-GM)群体大幅减少。为了确定病变主要是存在于干细胞中,还是也存在微环境成分,我们使用了德克斯特型长期骨髓培养。在这种培养中,正常骨髓可维持造血数周乃至数月,而“白消安处理的骨髓”则无法支持长期生长。当将正常骨髓细胞移植到已建立的贴壁层上时,无论该贴壁层源自正常骨髓还是白消安处理的骨髓,均可建立正常造血。然而,即使将白消安处理的骨髓细胞移植到正常干细胞耗竭的贴壁层上,也无法建立造血。因此,似乎白消安诱导的原发性病变存在于干细胞中,而非微环境中。